News & Updates

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

Individuals with multiple nevi and high genetic predisposition to melanoma appear to have the highest risks of developing second primary melanomas, according to a study.

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

A diagnosis of lung cancer can significantly worsen survival in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

Using a 4-day, fixed-dose schedule of filgrastim as granulocyte-colony stimulating factor (G-CSF) primary prophylaxis reduces the incidence of febrile neutropenia (FN) and associated hospitalization while maintaining the doses of adjuvant docetaxel and cyclophosphamide (TC) among Chinese women with early breast cancer (BC), a retrospective cohort study in Hong Kong has shown.

Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.